Setmelanotide: what it is and what the evidence says
An agonist of the melanocortin 4 receptor, the part of the leptin-melanocortin pathway that regulates appetite in the hypothalamus.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilising stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Obesity of confirmed genetic cause.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
A melanocortin 4 receptor agonist with solid but deliberately narrow evidence: two single-arm phase 3 trials demonstrated efficacy in severe obesity due to POMC or LEPR deficiency, and the VENTURE trial extended it to children aged 2 to 5.
The limitation that matters most
It only works in monogenic or syndromic obesity with a disrupted leptin-melanocortin pathway, CONFIRMED by genetic testing: this is not a drug for common obesity. The pivotal trials were single-arm with no placebo, and skin hyperpigmentation is a characteristic adverse effect.
Regulatory status
Approved by the FDA and the EMA (Imcivree) for obesity due to genetically confirmed POMC, PCSK1 or LEPR deficiency, and for Bardet-Biedl syndrome.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Only for monogenic or syndromic obesity with a genetic diagnosis. It is not a drug for common obesity.
The first step is genetic testing ordered by an endocrinologist, because without an identified mutation in the leptin-melanocortin pathway the indication does not apply.
What this page cannot give you
A reference page can take you this far. You know what Setmelanotide is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trialshuman Lancet Diabetes Endocrinol · 2020 · PMID 33137293 →
- Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trialhuman Lancet Diabetes Endocrinol · 2025 · PMID 39549719 →
- Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiencyhuman Orphanet J Rare Dis · 2022 · PMID 35123544 →
- Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotidehuman J Endocr Soc · 2022 · PMID 35528826 →
- Real-World Efficacy and Safety of Setmelanotide in Adults With Monogenic or Syndromic Obesity: A Prospective Cohort Studyhuman Obesity (Silver Spring) · 2025 · PMID 40897637 →
- Setmelanotide: First Approvalreview Drugs · 2021 · PMID 33638809 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Setmelanotide or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Setmelanotide?
An agonist of the melanocortin 4 receptor, the part of the leptin-melanocortin pathway that regulates appetite in the hypothalamus. It is studied within the area of metabolic.
Is there human evidence for Setmelanotide?
A melanocortin 4 receptor agonist with solid but deliberately narrow evidence: two single-arm phase 3 trials demonstrated efficacy in severe obesity due to POMC or LEPR deficiency, and the VENTURE trial extended it to children aged 2 to 5.
Is it approved by any health agency?
Approved by the FDA and the EMA (Imcivree) for obesity due to genetically confirmed POMC, PCSK1 or LEPR deficiency, and for Bardet-Biedl syndrome.
What is the dose of Setmelanotide?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Setmelanotide is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.